Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study
Abstract
:1. Introduction
2. Experimental Section
2.1. Study Design
2.2. Subjects and Procedures
2.3. Statistical Data Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Cronin, K.A.; Lake, A.J.; Scott, S.; Sherman, R.L.; Noone, A.M.; Howlader, N.; Henley, S.J.; Anderson, R.N.; Firth, A.U.; Ma, J.; et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 2018, 124, 2785–2800. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akinyemiju, T.; Abera, S.; Ahmed, M.; Alam, N.; Alemayohu, M.A.; Allen, C.; Al-Raddadi, R.; Alvis-Guzman, N.; Amoako, Y.; Artaman, A.; et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017, 3, 1683–1691. [Google Scholar] [CrossRef] [PubMed]
- Capuano, G.; Daniele, B.; Gaeta, G.B.; Gallo, C.; Perrone, F. A New Prognostic System for Hepatocellular Carcinoma: A Retrospective Study of 435 Patients: The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 1998, 28, 751–755. [Google Scholar] [CrossRef]
- Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; et al. Lenvatinib Versus Sorafenib In First-line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-inferiority Trial. Lancet 2018, 391, 1163–1173. [Google Scholar] [CrossRef] [Green Version]
- Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905. [Google Scholar] [CrossRef]
- Finn, R.S.; Merle, P.; Granito, A.; Huang, Y.H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Gerolami, R.; Caparello, C.; et al. Outcomes of Sequential Treatment with Sorafenib Followed by Regorafenib for HCC: Additional Analyses From the Phase III RESORCE Trial. J. Hepatol. 2018, 69, 353–358. [Google Scholar] [CrossRef]
- Abou-Alfa, G.K.; Meyer, T.; Cheng, A.L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.W.; et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018, 379, 54–63. [Google Scholar] [CrossRef]
- Zhu, A.X.; Park, J.O.; Ryoo, B.Y.; Yen, C.J.; Poon, R.; Pastorelli, D.; Blanc, J.F.; Chung, H.C.; Baron, A.D.; Pfiffer, T.E.F.; et al. Ramucirumab Versus Placebo as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-line Therapy With Sorafenib (REACH): A Randomised, Double-blind, Multicenter, Phase 3 Trial. Lancet Oncol. 2015, 16, 859–870. [Google Scholar] [CrossRef]
- Zhu, A.X.; Kang, Y.K.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; Lim, H.Y.; et al. Ramucirumab After Sorafenib In Patients With Advanced Hepatocellular Carcinoma and Increased α-fetoprotein Concentrations (REACH-2): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. Lancet Oncol. 2019, 20, 282–296. [Google Scholar] [CrossRef]
- Finn, R.S.; Ryoo, B.Y.; Merle, P.; Kudo, M.; Bouattour, M.; Lim, H.Y.; Breder, V.; Edeline, J.; Chao, Y.; Ogasawara, S.; et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020, 38, 193–202. [Google Scholar] [CrossRef] [PubMed]
- He, A.R.; Yau, T.; Hsu, C.; Kang, Y.K.; Kim, T.Y.; Santoro, A.; Sangro, B.; Melero, I.; Kudo, M.; Hou, M.M.; et al. Nivolumab (NIVO) + Ipilimumab (IPI) Combination Therapy In Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC): Subgroup Analyses From CheckMate 040. J. Clin. Oncol. 2020, 38, 512. [Google Scholar] [CrossRef]
- El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T.Y.; Choo, S.P.; Trojan, J.; Welling, T.H.R.; et al. Nivolumab In Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-label, Non-comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet 2017, 389, 2492–2502. [Google Scholar] [CrossRef]
- Pinter, M.; Peck-Radosavljevic, M. Review Article: Systemic Treatment of Hepatocellular Carcinoma. Aliment. Pharmacol. Ther. 2018, 48, 598–609. [Google Scholar] [CrossRef] [Green Version]
- Yu, S.J. A Concise Review of Updated Guidelines Regarding The Management of Hepatocellular Carcinoma Around The World: 2010–2016. Clin. Mol. Hepatol. 2016, 22, 7–17. [Google Scholar] [CrossRef]
- Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al. Regorafenib For Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-blind, Placebo-controlled, Phase 3 trial. Lancet 2017, 389, 56–66. [Google Scholar] [CrossRef] [Green Version]
- Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved Survival With Ipilimumab In Patients With Metastatic Melanoma. N. Engl. J. Med. 2010, 363, 711–723. [Google Scholar] [CrossRef]
- Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T Immunotherapy for Castration-resistant Prostate Cancer. N. Engl. J. Med. 2010, 363, 411–422. [Google Scholar] [CrossRef] [Green Version]
- Terme, M.; Pernot, S.; Marcheteau, E.; Sandoval, F.; Benhamouda, N.; Colussi, O.; Dubreuil, O.; Carpentier, A.F.; Tartour, E.; Taieb, J. VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. Cancer Res. 2013, 73, 539. [Google Scholar] [CrossRef] [Green Version]
- Alfaro, C.; Suarez, N.; Gonzalez, A.; Solano, S.; Erro, L.; Dubrot, J.; Palazon, A.; Hervas-Stubbs, S.; Gurpide, A.; Lopez-Picazo, J.M.; et al. Influence of Bevacizumab, Sunitinib and Sorafenib as Single Agents or in Combination on The Inhibitory Effects of VEGF on Human Eendritic Cell Differentiation From Monocytes. Br. J. Cancer 2009, 100, 1111–1119. [Google Scholar] [CrossRef]
- Kaur, S.; Chang, T.; Singh, S.P.; Lim, L.; Mannan, P.; Garfield, S.H.; Pendrak, M.L.; Soto-Pantoja, D.R.; Rosenberg, A.Z.; Jin, S.; et al. CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells. J. Immunol. 2014, 193, 3914. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Du Four, S.; Maenhout, S.K.; De Pierre, K.; Renmans, D.; Niclou, S.P.; Thielemans, K.; Neyns, B.; Aerts, J.L. Axitinib Increases The Infiltration of Immune Cells and Reduces The Suppressive Capacity of Monocytic MDSCs In An Intracranial Mouse Melanoma Model. OncoImmunology 2015, 4, e998107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Llovet, J.; Shepard, K.V.; Finn, R.S.; Ikeda, M.; Sung, M.; Baron, A.D.; Kudo, M.; Okusaka, T.; Kobayashi, M.; Kumada, H.; et al. A Phase Ib Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) In Unresectable Hepatocellular Carcinoma (uHCC): Updated Results. Ann. Oncol. 2019, 30, v286–v287. [Google Scholar] [CrossRef]
- Yau, T.; Zagonel, V.; Santoro, A.; Acosta-Rivera, M.; Choo, S.P.; Matilla, A.; He, A.R.; Gracián, A.C.; El-Khoueiry, A.B.; Sangro, B.; et al. Nivolumab (NIVO) + Ipilimumab (IPI) + Cabozantinib (CABO) Combination Therapy In Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC): Results From CheckMate 040. J. Clin. Oncol. 2020, 38, 478. [Google Scholar] [CrossRef]
- Saeed, A.; Phadnis, M.; Park, R.; Sun, W.; Al-Rajabi, R.M.d.T.; Baranda, J.C.; Williamson, S.K.; Collins, Z.; Firth-Braun, J.; Saeed, A.; et al. Cabozantinib (cabo) Combined With Durvalumab (durva) In Gastroesophageal (GE) Cancer and Other Gastrointestinal (GI) Malignancies: Preliminary Phase Ib CAMILLA Study Results. J. Clin. Oncol. 2020, 38, 4563. [Google Scholar] [CrossRef]
- Gruener, N.H.; Lechner, F.; Jung, M.C.; Diepolder, H.; Gerlach, T.; Lauer, G.; Walker, B.; Sullivan, J.; Phillips, R.; Pape, G.R.; et al. Sustained Dysfunction of Antiviral CD8+ T Lymphocytes After Infection with Hepatitis C Virus. J. Virol. 2001, 75, 5550–5558. [Google Scholar] [CrossRef] [Green Version]
- Wedemeyer, H.; He, X.S.; Nascimbeni, M.; Davis, A.R.; Greenberg, H.B.; Hoofnagle, J.H.; Liang, T.J.; Alter, H.; Rehermann, B. Impaired Effector Function of Hepatitis C Virus-specific CD8+ T Cells in Chronic Hepatitis C Virus Infection. J. Immunol. 2002, 169, 3447–3458. [Google Scholar] [CrossRef] [Green Version]
- Penna, A.; Pilli, M.; Zerbini, A.; Orlandini, A.; Mezzadri, S.; Sacchelli, L.; Missale, G.; Ferrari, C. Dysfunction and Functional Restoration of HCV-specific CD8 Responses in Chronic Hepatitis C Virus Infection. Hepatology 2007, 45, 588–601. [Google Scholar] [CrossRef]
- Fuller, M.J.; Callendret, B.; Zhu, B.; Freeman, G.J.; Hasselschwert, D.L.; Satterfield, W.; Sharpe, A.H.; Dustin, L.B.; Rice, C.M.; Grakoui, A.; et al. Immunotherapy of Chronic Hepatitis C Virus Infection with Antibodies Against Programmed Cell Death-1 (PD-1). Proc. Natl. Acad. Sci. USA 2013, 110, 15001–15006. [Google Scholar] [CrossRef] [Green Version]
- Kudo, M.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.H.; Verslype, C.; Zagonel, V.; Fartoux, L.; Vogel, A.; et al. Updated Efficacy and Safety of KEYNOTE-224: A Phase II Study of Pembrolizumab (Pembro) in Patients with Advanced Hepatocellular Carcinoma (HCC). J. Clin. Oncol. 2020, 38, 518. [Google Scholar] [CrossRef]
1st Line | # (%) | 2nd Line | # (%) |
---|---|---|---|
Sorafenib/Lenvatinib | 88 (89.8) | Nivolumab | 33 (37.5) |
Pembrolizumab | 8 (9.1) | ||
Regorafenib | 18 (20.5) | ||
Cabozantinib | 20 (22.7) | ||
Ramucirumab | 9 (10.2) | ||
Nivolumab | 10 (10.2) | Sorafenib (100%) | 10 (100) |
Baseline Characteristics | Total | Non-IO | IO | p-Value |
---|---|---|---|---|
Number | 98 | 57 | 41 | - |
Age (mean) | 61.9 | 61.6 | 62.3 | 0.76 |
Gender (Female) | 21.4% | 17.5% | 26.8% | 0.26 |
ECOG * (0–1) | 81.6% | 80.7% | 82.9% | 0.45 |
Child Pugh > B7 | 16.3% | 17.5% | 14.6% | 0.15 |
MELD ** score (mean) | 14.6 | 14.7 | 14.4 | 0.86 |
AFP *** (mean) | 7982 | 10,951 | 3898 | 0.29 |
Etiology of Liver Disease | ||||
Hepatitis C | 56.1% | 57.9% | 53.7% | 0.67 |
Hepatitis B | 6.1% | 5.3% | 7.3% | |
Alcohol | 28.6% | 31.6% | 22.0% | |
Other | 9.2% | 3.5% | 17.1% | |
Previous Treatments | ||||
Sorafenib | 87.8% | 98.2% | 73.2% | <0.01 |
Surgery | 5.1% | 3.5% | 7.3% | 0.39 |
Regional | 57.1% | 47.4% | 70.7% | 0.03 |
Extrahepatic Metastasis | 22.4% | 17.5% | 29.3% | 0.73 |
Baseline Characteristics | Total | Non-IO | IO | p-Value |
---|---|---|---|---|
Number | 55 | 33 | 22 | - |
Age (mean) | 62.1 | 61.8 | 62.4 | 0.45 |
Gender (Female) | 21.8% | 18.2% | 22.7% | 0.41 |
ECOG * (0–1) | 67.3% | 60.6% | 77.3% | 0.32 |
Child Pugh > B7 | 34.5% | 33.3% | 36.4% | 0.42 |
MELD ** score (mean) | 15 | 15.7 | 14.3 | 0.41 |
AFP *** (mean) | 10,024 | 12,482 | 7565 | 0.50 |
Previous Treatments | ||||
Sorafenib | 91% | 93.9% | 86.4% | 0.12 |
Surgery | 3.6% | 3.0% | 4.5% | 0.48 |
Regional | 63.6% | 57.6% | 72.7% | 0.09 |
Extrahepatic Metastasis | 41.8% | 39.4% | 45.5% | 0.44 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saeed, A.; Hildebrand, H.; Park, R.; Al-Jumayli, M.; Abbasi, S.; Melancon, T.; Saeed, A.; Al-Rajabi, R.; Kasi, A.; Baranda, J.; et al. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. J. Clin. Med. 2020, 9, 2682. https://doi.org/10.3390/jcm9092682
Saeed A, Hildebrand H, Park R, Al-Jumayli M, Abbasi S, Melancon T, Saeed A, Al-Rajabi R, Kasi A, Baranda J, et al. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. Journal of Clinical Medicine. 2020; 9(9):2682. https://doi.org/10.3390/jcm9092682
Chicago/Turabian StyleSaeed, Anwaar, Hannah Hildebrand, Robin Park, Mohammed Al-Jumayli, Saqib Abbasi, Tina Melancon, Azhar Saeed, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, and et al. 2020. "Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study" Journal of Clinical Medicine 9, no. 9: 2682. https://doi.org/10.3390/jcm9092682